Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern cooperative oncology group study e1393

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1088-1095

  Forastiere, A A ^a   Leong, T ^a   Rowinsky, E ^a   Murphy, B A ^a   Vlock, D R ^a   DeConti, R C ^a   Adams, G L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035865304     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1088     Document Type: Article

References (17)

1. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study
2. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
3. Randomized comparison of cisplatin, methotrexate, Neomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Center Cooperative Group
4. Adjuvant chemotherapy for resectable squamous cell carcinoma of the head and neck: Report on Intergroup Study 0034
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
6. Tumors of the larynx and hypopharynx
7. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer
8. Radiotherapy and concurrent chemotherapy: A strategy that improves locoregional control and survival in oropharyngeal cancer
9. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA390)
10. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-granulocyte-colony-stimulating factor versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group trial
11. A randomized trial of paclitaxel at 2 dose level and Filgastrim (G; G-GSF) at 2 dose levels in platinum pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCTTG and ECOG study
12. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
13. Failure of higher dose pactitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
14. On pushing the outer edge of the outer edge of paclitaxel's dosing envelope
15. Paclitaxel steady-state plasma concentration as a determinant or disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin
16. A phase I and pharmacology study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting
17. Randomized phase II trial of methorrexate (MTX) versus two schedules of paclitaxel (TAXOL) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)